Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms by Grünwald, Viktor, Powles, Thomas, Eto, Masatoshi, Kopyltsov, Evgeny, Rha, Sun Young, Porta, Camillo, Motzer, Robert, Hutson, Thomas E, Méndez-Vidal, María José, Hong, Sung-Hoo, Winquist, Eric, Goh, Jeffrey C, Maroto, Pablo, Buchler, Tomas, Takagi, Toshio, Burgents, Joseph E, Perini, Rodolfo, He, Cixin, Okpara, Chinyere E, McKenzie, Jodi, Choueiri, Toni K

Get full text

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial by Fizazi, Karim, Retz, Margitta, Petrylak, Daniel P, Goh, Jeffrey C, Perez-Gracia, Jose, Lacombe, Louis, Zschäbitz, Stefanie, Burotto, Mauricio, Mahammedi, Hakim, Gravis, Gwenaelle, Bastos, Diogo Assed, McCune, Steven L, Vázquez Limón, Juan Carlos, Kwan, Edmond M, Castellano, Daniel, Fléchon, Aude, Saad, Fred, Grimm, Marc-Oliver, Shaffer, David R, Armstrong, Andrew J, Bhagavatheeswaran, Prabhu, Amin, Neha P, Ünsal-Kaçmaz, Keziban, Wang, Xuya, Li, Jun, Loehr, Andrea, Pachynski, Russell K

Get full text

Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms by Grünwald, Viktor, Powles, Thomas, Eto, Masatoshi, Kopyltsov, Evgeny, Rha, Sun Young, Porta, Camillo, Motzer, Robert, Hutson, Thomas E, Méndez-Vidal, María José, Hong, Sung-Hoo, Winquist, Eric, Goh, Jeffrey C, Maroto, Pablo, Buchler, Tomas, Takagi, Toshio, Burgents, Joseph E, Perini, Rodolfo, He, Cixin, Okpara, Chinyere E, McKenzie, Jodi, Choueiri, Toni K

Get full text

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial by Coleman, Robert L, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, O'Malley, David M, Armstrong, Deborah K, Garcia-Donas, Jesus, Swisher, Elizabeth M, Floquet, Anne, Konecny, Gottfried E, McNeish, Iain A, Scott, Clare L, Cameron, Terri, Maloney, Lara, Goble, Sandra, Grace, Caroline, Harding, Thomas C, Raponi, Mitch, Sun, James, Lin, Kevin K, Giordano, Heidi, Ledermann, Jonathan A, Buck, M, Dean, A, Friedlander, M L, Harnett, P, Scott, C L, Dirix, L, Vergote, I, Elit, L, Ghatage, P, Oza, A M, Plante, M, Provencher, D, Weberpals, J I, Floquet, A, Joly, F, Leary, A, Medioni, J, Tredan, O, You, B, El-Balat, A, Hänle, C, Krabisch, P, Neunhöffer, T, Pölcher, M, Wimberger, P, Amit, A, Kovel, S, Leviov, M, Safra, T, Shapira-Frommer, R, Stemmer, S, Bologna, A, Colombo, N, Lorusso, D, Sabbatini, R F, Scambia, G, Tamberi, S, Zamagni, C, Fong, P C, O'Donnell, A, Gancedo, M Amenedo, Garcia-Donas, J, Guerra, E M, Oaknin, A, Palacio, I, Romero, I, Sanchez, A, Banerjee, S N, Drew, Y, Jackson, D, Ledermann, J A, McNeish, I A, Parkinson, C, Powell, M, Buss, M K, Chambers, S K, Chen, L-m, Coleman, R L, Holloway, R W, Konecny, G E, Ma, L, Morgan, M A, Morris, R T, O'Malley, D M, Slomovitz, B M, Swisher, E M, Vanderkwaak, T, Vulfovich, M

Get full text

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial by Hofman, Michael S, Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ng, Siobhan, Francis, Roslyn J, Gedye, Craig, Rutherford, Natalie K, Weickhardt, Andrew, Scott, Andrew M, Lee, Sze-Ting, Kwan, Edmond M, Azad, Arun A, Ramdave, Shakher, Redfern, Andrew D, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y, McJannett, Margaret M, Stockler, Martin R, Violet, John A, Williams, Scott G, Martin, Andrew J, Davis, Ian D, Azad, Arun A, Chua, Wei, Davis, Ian D, Dhiantravan, Nattakorn, Emmett, Louise, Ford, Kate, Hofman, Michael S, Francis, Roslyn J, Gedye, Craig, Goh, Jeffrey C, Guminski, Alex, Hsiao, Edward, Iravani, Amir, Joshua, Anthony M, Kirkwood, Ian D, Langford, Ailsa, Lawrence, Nicola, Lee, Sze-Ting, Lin, Peter, Martin, Andrew J, McDonald, William, McJannett, Margaret M, Ng, Siobhan, Pattison, David A, Ramdave, Shakher, Rana, Nisha, Redfern, Andrew D, Rutherford, Natalie K, Sandhu, Shahneen, Scott, Andrew M, Stockler, Martin R, Subramaniam, Shalini, Tan, Thean Hsiang, Violet, John A, Weickhardt, Andrew, Williams, Scott G, Yip, Sonia, Zhang, Alison Y

Get full text

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial by Motzer, Robert J, Russo, Paul, Grünwald, Viktor, Tomita, Yoshihiko, Zurawski, Bogdan, Parikh, Omi, Buti, Sebastiano, Barthélémy, Philippe, Goh, Jeffrey C, Ye, Dingwei, Lingua, Alejo, Lattouf, Jean-Baptiste, Albigès, Laurence, George, Saby, Shuch, Brian, Sosman, Jeffrey, Staehler, Michael, Vázquez Estévez, Sergio, Simsek, Burcin, Spiridigliozzi, Julia, Chudnovsky, Aleksander, Bex, Axel

Get full text

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open... by Choueiri, Toni K, Eto, Masatoshi, Motzer, Robert, De Giorgi, Ugo, Buchler, Tomas, Basappa, Naveen S, Méndez-Vidal, María José, Tjulandin, Sergei, Hoon Park, Se, Melichar, Bohuslav, Hutson, Thomas, Alemany, Carlos, McGregor, Bradley, Powles, Thomas, Grünwald, Viktor, Alekseev, Boris, Rha, Sun Young, Kopyltsov, Evgeny, Kapoor, Anil, Alonso Gordoa, Teresa, Goh, Jeffrey C, Staehler, Michael, Merchan, Jaime R, Xie, Ran, Perini, Rodolfo F, Mody, Kalgi, McKenzie, Jodi, Porta, Camillo G

Get full text

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a bio... by Buteau, James P, Martin, Andrew J, Emmett, Louise, Iravani, Amir, Sandhu, Shahneen, Joshua, Anthony M, Francis, Roslyn J, Zhang, Alison Y, Scott, Andrew M, Lee, Sze-Ting, Azad, Arun A, McJannett, Margaret M, Stockler, Martin R, Williams, Scott G, Davis, Ian D, Hofman, Michael S, Akhurst, Tim, Alipour, Ramin, Azad, Arun A, Banks, Patricia, Beaulieu, Alexis, Buteau, James P, Chua, Wei, Davis, Ian D, Dhiantravan, Nattakorn, Emmett, Louise, Ford, Kate, Hofman, Michael S, Francis, Roslyn J, Gedye, Craig, Goh, Jeffrey C, Guminski, Alex, Hamid, Anis, Haskali, Mohammad B, Hicks, Rodney J, Hsiao, Edward, Iravani, Amir, Joshua, Anthony M, Kirkwood, Ian D, Kong, Grace, Kwan, Edmond M, Langford, Ailsa, Lawrence, Nicola, Lee, Sze-Ting, Lewin, Jeremy, Lin, Peter, Martin, Andrew J, McDonald, William, McJannett, Margaret M, Moodie, Kate, Murphy, Declan G, Ng, Siobhan, Pattison, David A, Pokorski, Izabella, Ramdave, Shakher, Ravi Kumar, Aravind S, Redfern, Andrew D, Rutherford, Natalie K, Saghebi, Javad, Sandhu, Shahneen, Scott, Andrew M, Spain, Lavinia, Stockler, Martin R, Subramaniam, Shalini, Tan, Thean Hsiang, Thang, Sue Ping, Tran, Ben, Wallace, Roslyn, Weickhardt, Andrew, Williams, Scott G, Yip, Sonia, Zhang, Alison Y

Get full text

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease... by Oaknin, Ana, Oza, Amit M., Lorusso, Domenica, Aghajanian, Carol, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I., Clamp, Andrew R., Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W., Amenedo Gancedo, Margarita, Fong, Peter C., Goh, Jeffrey C., O’Malley, David M., Armstrong, Deborah K., Banerjee, Susana, García‐Donas, Jesus, Swisher, Elizabeth M., Cameron, Terri, Maloney, Lara, Goble, Sandra, Ledermann, Jonathan A., Coleman, Robert L.

Get full text

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, ph... by Ledermann, Jonathan A, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew R, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, O'Malley, David M, Armstrong, Deborah K, Banerjee, Susana, García-Donas, Jesus, Swisher, Elizabeth M, Cameron, Terri, Maloney, Lara, Goble, Sandra, Coleman, Robert L

Get full text

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial by Shannon, Catherine M, Joly, Florence, Sehouli, Jalid, Canzler, Ulrich, Schmalfeldt, Barbara, Dean, Andrew P, Hein, Alexander, Zeimet, Alain G, Petit, Thierry, Marmé, Frederik, El-Balat, Ahmed, Glasspool, Rosalind, Mahner, Sven, Park-Simon, Tjoung-Won, Mouret-Reynier, Marie-Ange, Costan, Cristina, Reinthaller, Alexander, Goh, Jeffrey C, Kommoss, Stefan, Kurtz, Jean-Emmanuel, Ackermann, Sven, Anthuber, Christoph, Aydogdu, Mustafa, Baldauf, Angelika, Behringer, Dirk, Belau, Antje, Bender, Alexandra, Burges, Alexander, Canzler, Ulrich, Daabach, Trygve, Deryal, Mustafa, El-Balat, Ahmed, Fehm, Tanja, Feisel-Schwickardi, Gabriele, Frank, Matthias, Gebauer, Gerhard, Gerber, Bernd, Gerhardt, Axel, Grafe, Andrea, Griesshammer, Martin, Gropp-Meier, Martina, Hager, Dietrich, Hannig, Carla Verena, Hantschmann, Peer, Harter, Philipp, Hauzenberger, Tanja, Herwig, Uwe, Hilpert, Felix, Jackisch, Christian, Krieger, Peter, Lampe, Björn, Lex, Benno, Lorenz, Ralf, Mahner, Sven, Mallmann, Peter, Marmé, Frederik, Möbus, Volker, Müller, Thomas, Neunhöffer, Tanja, Ober, Angelika, Rautenberg, Beate, Reiter, Wilhelm, Schmalfeldt, Barbara, Scholz, Heinz, Simon, Eike, Sperfeld, Antje, Terhaag, Jürgen, Uleer, Christoph, Vogel, Susanne, Voß, Hermann, Winkler, Ulrich, Wischnik, Arthur, Zorr, Andreas, Glasspool, Ros, Jones, Rachel, Lafleur, Judith, Marth, Christian, Baron-Hay, Sally, Beale, Philip, Begbie, Stephen, Harvey, Sandra, Matos, Marco, Meniawy, Tarek, Olesen, Inger, Shannon, Catherine, Abadie-Lacourtoisie, Sophie, Arsene, Olivier, Barthier, Sophie, Catala, Stéphanie, Dohollou, Nadine, Garnier-Tixidré, Claire, Guardiola, Emmanuel, Hardy-Bessard, Anne-Claire, Joly, Florence, Levache, Charles-Briac, Longo, Raffaele, Lortholary, Alain, Meunier, Jérôme, Raban, Nadia, Vannetzel, Jean-Michel

Get full text

Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomis... by Motzer, Robert, Porta, Camillo, Alekseev, Boris, Rha, Sun Young, Choueiri, Toni K, Mendez-Vidal, Maria Jose, Hong, Sung-Hoo, Kapoor, Anil, Goh, Jeffrey C, Eto, Masatoshi, Bennett, Lee, Wang, Jinyi, Pan, Jie Janice, Saretsky, Todd L, Perini, Rodolfo F, He, Cixin Steven, Mody, Kalgi, Cella, David

Get full text

Overall survival with [ 177 Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 t... by Hofman, Michael S, Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P, Joshua, Anthony M, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ng, Siobhan, Francis, Roslyn J, Gedye, Craig, Rutherford, Natalie K, Weickhardt, Andrew, Scott, Andrew M, Lee, Sze-Ting, Kwan, Edmond M, Azad, Arun A, Ramdave, Shakher, Redfern, Andrew D, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Yan, Stockler, Martin R, Williams, Scott G, Martin, Andrew J, Davis, Ian D

Get full text

Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer by Blagden, Sarah P, Hamilton, Anne L, Mileshkin, Linda, Wong, Shirley, Michael, Agnieszka, Hall, Marcia, Goh, Jeffrey C, Lisyanskaya, Alla S, DeSilvio, Michelle, Frangou, Eleni, Stronach, Euan A, Gopalakrishna, Prashanth, Meniawy, Tarek M, Gabra, Hani

Get full text

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial by Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia, Butler, Patrick, Zhang, Alison Yan, Yip, Sonia, Thomas, Hayley, Langford, Ailsa, Hofman, Michael S, McJannett, Margaret, Martin, Andrew James, Stockler, Martin R, Davis, Ian D

Get full text

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma by O'Malley, David M, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew R, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, Swisher, Elizabeth M, Maloney, Lara, Goble, Sandra, Lin, Kevin K, Kwan, Tanya, Ledermann, Jonathan A, Coleman, Robert L

Get full text

A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ov... by Banerjee, Susana N., Tang, Monica, O'Connell, Rachel L., Sjoquist, Katrin, Clamp, Andrew R., Millan, David, Nottley, Steven, Lord, Rosemary, Mullassery, Vinod Menon, Hall, Marcia, Gourley, Charlie, Bonaventura, Tony, Goh, Jeffrey C., Sykes, Peter, Grant, Peter T., McNally, Orla, Alexander, Laura, Kelly, Caroline, Carty, Karen, Divers, Laura, Bradshaw, N., Edmondson, Richard J., Friedlander, Michael

Get full text

Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management by Pathmanathan, Shivanshan, Tariq, Arsalan, Pearce, Adam, Rhee, Handoo, Kyle, Samuel, Raveenthiran, Sheliyan, Wong, David, McBean, Rhiannon, Marsh, Phillip, Goodman, Steven, Dhiantravan, Nattakorn, Esler, Rachel, Dunglison, Nigel, Navaratnam, Anojan, Yaxley, John, Thomas, Paul, Pattison, David A., Goh, Jeffrey C., Gan, Chun Loo, Roberts, Matthew J.

Get full text

A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non‐clear‐cell renal cell carcinoma by Conduit, Ciara, Davis, Ian D., Goh, Jeffrey C., Kichenadasse, Ganessan, Gurney, Howard, Harris, Carole A., Pook, David, Krieger, Laurence, Parnis, Francis, Underhill, Craig, Adams, Diana, Roncolato, Felicia, Joshua, Anthony, Ferguson, Tom, Prithviraj, Prashanth, Morris, Michelle, Harrison, Michelle, Begbie, Stephen, Hovey, Elizabeth, George, Mathew, Liow, Elizabeth C., Link, Emma K., McJannett, Margaret, Gedye, Craig

Get full text

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients... by Colombo, Nicoletta, Oza, Amit M., Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Weberpals, Johanne I., Clamp, Andrew R., Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W., Gancedo, Margarita Amenedo, Fong, Peter C., Goh, Jeffrey C., O'Malley, David M., Armstrong, Deborah K., Banerjee, Susana, García-Donas, Jesus, Swisher, Elizabeth M., Meunier, Juliette, Cameron, Terri, Maloney, Lara, Goble, Sandra, Bedel, Josh, Ledermann, Jonathan A., Coleman, Robert L.

Get full text